阿柏西普和雷珠单抗治疗视网膜分支静脉阻塞继发黄斑水肿患者的临床疗效对比

Comparison of clinical efficacy of aflibercept and ranibizumab in the treatment of macular edema secondary to branch retinal vein occlusion

目的对比分析阿柏西普(aflibercept)和雷珠单抗(ranibizumab)在治疗视网膜分支静脉阻塞(BRVO)继发黄斑水肿(ME)患者的临床疗效。方法回顾性病例研究。收集2018年11月至2020年4月期间就诊的BRVO合并ME的患者41例(41只眼),根据其行玻璃体阿柏西普注药术和雷珠单抗注药术分为阿柏西普组和雷珠单抗组,详细观察分析两组间术前及术后1、3、6个月的各临床指标资料。结果两组间患者术前最佳矫正视力(BCVA)、浆液性视网膜脱离(SRD)高度、黄斑中心凹陷(CSFT)比较无统计学差异(P<0.05),术后1个月,两组的BCVA,SRD高度和CSFT均优于术前,术后1、3、6个月,阿柏西普组较阿柏西普组的BCVA明显提高,SRD高度及CSFT明显降低,两者均有统计学差异(P<0.05)。6个月随访期间,阿柏西普组的平均注射针数较雷珠单抗组少,两组间比较有统计学差异(P<0.05)。结论阿柏西普在治疗BRVO-ME方面对改善患者BCVA、SRD高度和CSFT方面效果显著,较雷珠单抗有更好的优势。

Objective To compare the short clinical effect of aflibercept and ranibizumab in the treatment of macular edema(ME)secondary to branch retinal vein occlusion(BRVO).Methods Retrospective case study.Forty-one patients(41 eyes)with BRVO and secondary ME from November 2018 to April 2020 were collected.They were divided into aflibercept group and ranibizumab group.The postoperative clinical data between the two groups were observed and analyzed in detail.Results The best corrected visual acuity(BCVA),the height of serous retinal detachment(SRD)and central subfield thickness(CSFT)were not significantly different between the two groups before operation(P<0.05).Compared to ranibizumab group,at 1month,3months after operation,BCVA was significantly improved,CSFT and the height of SRD were significantly decreased in the aflibercept group(P<0.05).During the 6 months follow-up,the average number of injection in the aflibercept group was less than that in the ranibizumab group.Six months after operation,there was no significant difference in the recurrence rate of ME between the two groups(P<0.05).Conclusions Compared to ranibizumab,aflibercept was more effective in treating ME secondary to BRVO,which showed the favorable clinical outcomes with the improvement of CSFT,the height of SRD and BCVA.